| Basics |
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach & drug discovery capabilities to develop its products.
|
| IPO Date: |
March 21, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$108.8M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.93 | 2.20%
|
| Avg Daily Range (30 D): |
$0.17 | 3.15%
|
| Avg Daily Range (90 D): |
$0.21 | 3.40%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.19M |
| Avg Daily Volume (30 D): |
.21M |
| Avg Daily Volume (90 D): |
.38M |
| Trade Size |
| Avg Trade Size (Sh.): |
73 |
| Avg Trade Size (Sh.) (30 D): |
75 |
| Avg Trade Size (Sh.) (90 D): |
93 |
| Institutional Trades |
| Total Inst.Trades: |
2,594 |
| Avg Inst. Trade: |
$1.8M |
| Avg Inst. Trade (30 D): |
$.69M |
| Avg Inst. Trade (90 D): |
$1.63M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.92M |
| Avg Closing Trade (30 D): |
$.69M |
| Avg Closing Trade (90 D): |
$.92M |
| Avg Closing Volume: |
38.4K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-1.05
|
$-1.07
|
|
Diluted EPS
|
|
$-1.05
|
$-1.07
|
|
Revenue
|
$
|
$ 16.96M
|
$ 17.97M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -104.93M
|
$ -22.29M
|
$ -22.66M
|
|
Operating Income / Loss
|
$
|
$ -23.54M
|
$ -24.19M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 47.12M
|
$ -27.77M
|
|
PE Ratio
|
|
|
|
|
